-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Human epidermal growth factor receptor (HER2-positive) breast cancer accounts for about one-fifth of all breast cancers
Breast Cancer In the APT study, weekly paclitaxel + trastuzumab treatment of HER2 positive + tumor ≤ 3 cm + invisible lymph node patients, the 7-year disease-free survival rate was 93%
The purpose of this study was to compare trastuzumab ± chemotherapy after surgery for HER2-positive early breast cancer with tumors ≤ 2 cm and negative lymph nodes
The purpose of this study was to compare trastuzumab ± chemotherapy after surgery for HER2-positive early breast cancer with tumors ≤ 2 cm and negative lymph nodes
In the National Cancer Database (2004-2017), patients with a preliminary diagnosis of pT1N0M0 HER2-positive breast cancer were divided into two groups: (i) anti-HER2 monotherapy, namely trastuzumab, (ii) chemotherapy-trastuzumab Combination therapy with benzumab
In the National Cancer Database (2004-2017), patients with a preliminary diagnosis of pT1N0M0 HER2-positive breast cancer were divided into two groups: (i) anti-HER2 monotherapy, namely trastuzumab, (ii) chemotherapy-trastuzumab Combination therapy with benzumab
A total of 23281 patients met the criteria
A total of 23281 patients met the criteria
After matching, compared with trastuzumab monotherapy, patients with chemotherapy-trastuzumab combination therapy have a moderate survival advantage (5-year OS 94.
Therefore, the results of this big data review study show that for patients with HER2-positive early breast cancer with tumors ≤ 2 cm and negative lymph nodes, although trastuzumab combined with chemotherapy is compared with trastuzumab monotherapy, 5 years The overall survival rate is 3.
Therefore, the results of this big data review study show that for patients with HER2-positive early breast cancer with tumors ≤ 2 cm and negative lymph nodes, although trastuzumab combined with chemotherapy is compared with trastuzumab monotherapy, 5 years The overall survival rate is 3.
Original source:
Cao L, et al.
Breast Cancer Res Treat.
DOI: 10.
Leave a message here
